- Conditions
- Acute Bacterial Infections, Acute Viral Infections
- Interventions
- Not listed
- Lead sponsor
- The Plasma Source
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Southampton, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 10,802
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Granulomatous Disease, Chronic, X-linked
- Interventions
- Lentiviral G1XCGD Gene Therapy
- Biological
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 23 Months and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
- Conditions
- Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism, Multiple System Atrophy, Brain Tumor Adult, Spinal Cord Injuries, Locked-in Syndrome
- Interventions
- BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying, BCI-FIT language modeling
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
- Interventions
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Biological · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- vorinostat, gemtuzumab ozogamicin, azacitidine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Stanford, California • Bremerton, Washington • Seattle, Washington
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Spina Bifida, Cerebral Palsy, Genetic Disease, Spinal Cord Injuries, Gross Motor Development Delay, Motor Skills Disorders
- Interventions
- Manual Wheelchair Skills Training
- Other
- Lead sponsor
- Grand Valley State University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Urea Cycle Disorders, Carbamoyl-Phosphate Synthase I Deficiency
- Interventions
- LNP.UCD.ABE
- Biological
- Lead sponsor
- Rebecca Ahrens-Nicklas
- Other
- Eligibility
- 24 Hours to 5 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hemophilia A
- Interventions
- Damoctocog alfa pegol (Jivi, Bay94-9027)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
- Conditions
- Healthy, Sickle Cell Anemia
- Interventions
- Placebo, PF-07209326
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 26 more
- Conditions
- Sickle Cell Disease, Acute Chest Syndrome
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- OTC Drug for Atopic Dermatitis in Cream form
- Drug
- Lead sponsor
- Good Molecules, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- calfactant, isotonic saline
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria
- Interventions
- Autonomic Function Testing, Genetic Testing, Urine Testing, Blood laboratory Testing
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neurofibromatosis Type 1, Von Recklinghausen Disease, NF1
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Graft Versus Host Disease, Leukemia
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
- Interventions
- Not listed
- Lead sponsor
- Global Healthy Living Foundation
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Upper Nyack, New York
- Conditions
- Sickle Cell Disease, Asthma
- Interventions
- Not listed
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 6 Years to 20 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
- Conditions
- Pulmonary Hypertension
- Interventions
- Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
- Biological · Procedure
- Lead sponsor
- Timothy J Nelson, MD, PhD
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Vascular Malformations, VM - Vascular Malformation
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland